171 related articles for article (PubMed ID: 29891252)
1. Hypoxia and Noncoding RNAs in Taxane Resistance.
Pucci P; Rescigno P; Sumanasuriya S; de Bono J; Crea F
Trends Pharmacol Sci; 2018 Aug; 39(8):695-709. PubMed ID: 29891252
[TBL] [Abstract][Full Text] [Related]
2. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
3. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C
Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195
[TBL] [Abstract][Full Text] [Related]
4. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.
Giovinazzi S; Morozov VM; Summers MK; Reinhold WC; Ishov AM
Cell Death Differ; 2013 May; 20(5):721-31. PubMed ID: 23348568
[TBL] [Abstract][Full Text] [Related]
5. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Wang R; Wang H; Wang Z
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
[TBL] [Abstract][Full Text] [Related]
6. Taxane effect in a bladder washing.
Dustin SM; Jeffus SK; Stelow EB
Diagn Cytopathol; 2015 Jan; 43(1):32-3. PubMed ID: 24644138
[No Abstract] [Full Text] [Related]
7. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
Chien AJ; Moasser MM
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PubMed ID: 18410794
[TBL] [Abstract][Full Text] [Related]
8. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
Bartlett JM; Nielsen TO; Gao D; Gelmon KA; Quintayo MA; Starczynski J; Han L; Burnell MJ; Levine MN; Chen BE; Shepherd LE; Chapman JW;
Br J Cancer; 2015 Sep; 113(5):722-8. PubMed ID: 26284338
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: Bay-59-8862.
Eckstein JW
IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
[TBL] [Abstract][Full Text] [Related]
10. Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma.
Ren J; Wang R; Song H; Huang G; Chen L
Mol Med; 2014 Apr; 20(1):164-78. PubMed ID: 24643460
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic aberrations of ABCB1 synergistically boost the acquisition of taxane resistance in esophageal squamous cancer cells.
Sumarpo A; Ito K; Saiki Y; Ishizawa K; Wang R; Chen N; Sunamura M; Horii A
Biochem Biophys Res Commun; 2020 Jun; 526(3):586-591. PubMed ID: 32247608
[TBL] [Abstract][Full Text] [Related]
12. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
[TBL] [Abstract][Full Text] [Related]
13. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract][Full Text] [Related]
14. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer.
Chen W; Qin Y; Wang D; Zhou L; Liu Y; Chen S; Yin L; Xiao Y; Yao XH; Yang X; Ma W; Chen W; He X; Zhang L; Yang Q; Bian X; Shao ZM; Liu S
PLoS Biol; 2018 Jul; 16(7):e2005869. PubMed ID: 30052635
[TBL] [Abstract][Full Text] [Related]
15. Development of taxane resistance in a panel of human lung cancer cell lines.
Breen L; Murphy L; Keenan J; Clynes M
Toxicol In Vitro; 2008 Aug; 22(5):1234-41. PubMed ID: 18514476
[TBL] [Abstract][Full Text] [Related]
16. Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
[TBL] [Abstract][Full Text] [Related]
17. Tubulin interacting agents: novel taxanes and epothilones.
Agrawal NR; Ganapathi R; Mekhail T
Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
[TBL] [Abstract][Full Text] [Related]
18. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
von Minckwitz G; Martin M; Wilson G; Alba E; Schmidt M; Biganzoli L; Awada A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):315-31. PubMed ID: 23116625
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
Ito Y; Kobayashi K
Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNAs in Taxane Resistance of Breast Cancer.
Chen H; Zhang M; Deng Y
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
